Post-transplant immunotherapy: combining cancer vaccines with hematopoietic stem cell transplantation

References

• Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science313, 1960–1964 (2006).
   PubMed Web of Science ®Google Scholar
• Pages F, Berger A, Camus M et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med.353, 2654–2666 (2005).
   PubMed Web of Science ®Google Scholar
• Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas, with a report of ten original cases. Am. J. Med. Sci.105, 487–511 (1893).
   Google Scholar
• Titcomb CP Jr. High incidence of nasopharyngeal carcinoma in Asia. J. Insur. Med.33, 235–238 (2001).
   PubMedGoogle Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med.10, 909–915 (2004).
   PubMed Web of Science ®Google Scholar
• Fournier P, Schirrmacher V. Randomized clinical studies of anti-tumor vaccination: state of the art in 2008. Expert Rev. Vaccines8, 51–66 (2009).
   PubMed Web of Science ®Google Scholar
• Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer5, 263–274 (2005).
   PubMed Web of Science ®Google Scholar
• Ochsenbein AF, Klenerman P, Karrer U et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl Acad. Sci. USA96, 2233–2238 (1999).
   PubMed Web of Science ®Google Scholar
• Surh CD, Sprent J. Regulation of mature T cell homeostasis. Semin. Immunol.17, 183–191 (2005).
   PubMed Web of Science ®Google Scholar
• Symons HJ, Levy MY, Wang J et al. The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells. Biol. Blood Marrow Transplant.14, 499–509 (2008).
   PubMed Web of Science ®Google Scholar
• Bandera A, Trabattoni D, Pacei M et al. Fully immunocompetent CD8+ T lymphocytes are present in autologous haematopoietic stem cell transplantation recipients despite an ineffectual T-helper response. PLoS ONE3, e3616 (2008).
   Google Scholar
• Rapoport AP, Stadtmauer EA, Aqui N et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat. Med.11, 1230–1237 (2005).
   PubMed Web of Science ®Google Scholar
• Dudley ME, Yang JC, Sherry R et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol.26, 5233–5239 (2008).
   PubMed Web of Science ®Google Scholar
• Hambach L, Vermeij M, Buser A et al. Targeting a single mismatched minor histocompatibility antigen with tumor-restricted expression eradicates human solid tumors. Blood112, 1844–1852 (2008).
   PubMed Web of Science ®Google Scholar
• Bolanos-Meade J, Garrett-Mayer E, Luznik L et al. Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. Biol. Blood Marrow Transplant.13, 1185–1191 (2007).
   PubMed Web of Science ®Google Scholar
• Stein AS, O’Donnell MR, Slovak ML et al. Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission. J. Clin. Oncol.21, 615–623 (2003).
   PubMed Web of Science ®Google Scholar
• de Cerio AL, Inoges S. Future of idiotypic vaccination for B-cell lymphoma. Expert Rev. Vaccines8, 43–50 (2009).
   PubMed Web of Science ®Google Scholar
• Bendandi M, Rodriguez-Calvillo M, Inoges S et al. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leuk. Lymphoma47, 29–37 (2006).
   PubMed Web of Science ®Google Scholar
• Davis TA, Hsu FJ, Caspar CB et al. Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma. Biol. Blood Marrow Transplant.7, 517–522 (2001).
   PubMed Web of Science ®Google Scholar
• Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science314, 126–129 (2006).
   PubMed Web of Science ®Google Scholar
• Li J, Song W, Czerwinski DK et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J. Immunol.179, 2493–2500 (2007).
   PubMed Web of Science ®Google Scholar
• Brody JD, Goldstein MJ, Czerwinski DK, Levy R. Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors. Blood113, 85–94 (2009).
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Simpson JL, Chien CD, Gress RE. Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing homeostatic peripheral expansion after BMT. Blood110, 450–460 (2007).
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood76, 2462–2465 (1990).
   PubMed Web of Science ®Google Scholar
• Copelan EA. Hematopoietic stem-cell transplantation. N. Engl. J. Med.354, 1813–1826 (2006).
   PubMed Web of Science ®Google Scholar
• Rezvani K, Barrett AJ. Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation. Best Pract. Res. Clin. Haematol.21, 437–453 (2008).
   PubMed Web of Science ®Google Scholar
• Marijt E, Wafelman A, van der Hoorn M et al. Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation. Haematologica92, 72–80 (2007).
   PubMed Web of Science ®Google Scholar
• Rezvani K, Yong AS, Mielke S et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood111, 236–242 (2008).
   PubMed Web of Science ®Google Scholar
• Marijt WA, Heemskerk MH, Kloosterboer FM et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc. Natl Acad. Sci. USA100, 2742–2747 (2003).
   PubMed Web of Science ®Google Scholar
• Hambach L, Ling KW, Pool J et al. Hypomethylating drugs convert HA-1 negative solid tumors into targets for stem cell based immunotherapy. Blood113(12), 2715–2722 (2008).
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science295, 2097–2100 (2002).
   PubMed Web of Science ®Google Scholar
• Porter DL, Levine BL, Bunin N et al. A Phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood107, 1325–1331 (2006).
   PubMed Web of Science ®Google Scholar
• Buhmann R, Simoes B, Stanglmaier M et al. Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 × anti-CD20 antibody and donor lymphocyte infusion. Bone Marrow Transplant43(5), 383–397 (2008).
   PubMed Web of Science ®Google Scholar
• Posthuma EF, Marijt EW, Barge RM et al. α-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease. Biol. Blood Marrow Transplant.10, 204–212 (2004).
   PubMed Web of Science ®Google Scholar
• Cabrera R, Diaz-Espada F, Barrios Y et al. Infusion of lymphocytes obtained from a donor immunised with the paraprotein idiotype as a treatment in a relapsed myeloma. Bone Marrow Transplant25, 1105–1108 (2000).
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Munshi NC, Jagannath S et al. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transplant36, 315–323 (2005).
   PubMed Web of Science ®Google Scholar
• Eckl-Dorna J, Batista FD. BCR-mediated uptake of antigen linked to TLR9-ligand stimulates B-cell proliferation and antigen-specific plasma cell formation. Blood DOI: 0: blood-2008-10-185421v1 (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Paget C, Bialecki E, Fontaine J et al. Role of invariant NK T lymphocytes in immune responses to CpG oligodeoxynucleotides. J. Immunol.182, 1846–1853 (2009).
   PubMed Web of Science ®Google Scholar
• Nieda M, Okai M, Tazbirkova A et al. Therapeutic activation of Vα24+Vβ11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood103, 383–389 (2004).
   PubMed Web of Science ®Google Scholar
• Ishikawa A, Motohashi S, Ishikawa E et al. A Phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res.11, 1910–1917 (2005).
   PubMed Web of Science ®Google Scholar
• Ko HJ, Lee JM, Kim YJ et al. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine. J. Immunol.182, 1818–1828 (2009).
   PubMed Web of Science ®Google Scholar
• Morse MA, Hobeika AC, Osada T et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood112, 610–618 (2008).
   PubMed Web of Science ®Google Scholar
• Dannull J, Su Z, Rizzieri D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest.115, 3623–3633 (2005).
   PubMed Web of Science ®Google Scholar
• Correale P, Tagliaferri P, Fioravanti A et al. Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial). Clin. Cancer. Res.14, 4192–4199 (2008).
   PubMed Web of Science ®Google Scholar
• Beyer M, Kochanek M, Darabi K et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood106, 2018–2025 (2005).
   PubMed Web of Science ®Google Scholar
• Kottke T, Thompson J, Diaz RM et al. Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2. Clin. Cancer Res.15, 561–569 (2009).
   PubMed Web of Science ®Google Scholar
• Luznik L, Fuchs EJ, Chen AR et al. Post-translpantation high-dose cyclophosphamide (CY) is effective single agent GvHD prophylaxis that permits prompt immune reconstitution after myeloablative HLA matched related and unrelated bone marrow transplantation (BMT). Biol. Blood Marrow Transplant.13, 4 (2007).
   Web of Science ®Google Scholar
• Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat. Med.10, 475–480 (2004).
   PubMed Web of Science ®Google Scholar
• Oelke M, Maus MV, Didiano D et al.Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat. Med.9, 619–624 (2003).
   PubMed Web of Science ®Google Scholar
• von Bergwelt-Baildon MS, Vonderheide RH, Maecker B et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood99, 3319–3325 (2002).
   PubMed Web of Science ®Google Scholar